Fda approves renewal of canalevia-ca1, jaguar health's drug for chemotherapy-induced diarrhea in dogs

Canalevia®-ca1 is the first and only treatment for chemotherapy-induced diarrhea (cid) in dogs to receive any type of approval from the fda by prescription only, canalevia-ca1 is a canine-specific formulation of crofelemer, jaguar's novel, oral plant-based product sustainably harvested from the croton lechleri tree san francisco, ca / accesswire / november 6, 2024 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that the u.s. food and drug administration (fda) has approved renewal of canalevia-ca1 (crofelemer delayed-release tablets). canalevia-ca1, the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (cid) in dogs, is available from multiple leading veterinary distributors in the u.s., including chewy.
JAGX Ratings Summary
JAGX Quant Ranking